Your shopping cart is currently empty

Arginyl-Glutamine TFA is a dipeptide that can reduce VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Arginyl-Glutamine TFA is a dipeptide that can reduce VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy. |
| In vitro | Arginyl-Glutamine TFA (0.5-1.5 mM; 48 h) significantly reduces the expression of soluble VEGF in the medium of cultured human RPE cells in a dose-dependent manner. |
| In vivo | Administering Arginyl-Glutamine TFA (1-5 g/kg/day, as a hydrochloride salt; i.p.; twice daily) significantly inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy (OIR). |
| Sequence | Arg-Gln |
| Sequence Short | RQ |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.